within Pharmacolibrary.Drugs.ATC.C;

model C02CA06
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00013166666666666668,
    adminDuration  = 600,
    adminMass      = 25 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00087,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00109,
    k12             = 0.091,
    k21             = 0.091
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C02CA06</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Urapidil is an antihypertensive agent acting as an alpha-1 adrenergic receptor antagonist and 5-HT1A receptor agonist. It is mainly used for the treatment of acute and chronic hypertension. Urapidil is not approved by the US FDA but is used in several European countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters of urapidil after intravenous administration in healthy adult male volunteers.</p><h4>References</h4><ol><li><p>Dooley, M, &amp; Goa, KL (1998). Urapidil. A reappraisal of its use in the management of hypertension. <i>Drugs</i> 56(5) 929–955. DOI:<a href=\"https://doi.org/10.2165/00003495-199856050-00016\">10.2165/00003495-199856050-00016</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9829161/\">https://pubmed.ncbi.nlm.nih.gov/9829161</a></p></li><li><p>Prichard, BN, et al., &amp; Renondin, JC (1989). Urapidil, a multiple-action alpha-blocking drug. <i>The American journal of cardiology</i> 64(7) 11D–15D. DOI:<a href=\"https://doi.org/10.1016/0002-9149(89)90689-9\">10.1016/0002-9149(89)90689-9</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2569263/\">https://pubmed.ncbi.nlm.nih.gov/2569263</a></p></li><li><p>Bottorff, MB, et al., &amp; Ramanathan, KB (1988). Pharmacokinetics and pharmacodynamics of urapidil in severe hypertension. <i>Journal of clinical pharmacology</i> 28(5) 420–426. DOI:<a href=\"https://doi.org/10.1002/j.1552-4604.1988.tb05753.x\">10.1002/j.1552-4604.1988.tb05753.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3392239/\">https://pubmed.ncbi.nlm.nih.gov/3392239</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C02CA06;
